Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

ClinicalTrials.gov ID: NCT05022784

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05022784. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Real-World Medication Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: * Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. * Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.

Study identification

NCT ID: NCT05022784
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 1,798 participants

Conditions and interventions

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

Nintedanib Drug

Drug

Eligibility (public fields only)

Age range: 66 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 23, 2021 (Actual)
Primary completion: Dec 30, 2021 (Actual)
Completion: Dec 30, 2021 (Actual)
Last update posted: Apr 19, 2024

2021

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Medicus Economics, LCC	Milton	Massachusetts	02186	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05022784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2024 · Synced Nov 14, 2026